Biogen (BIIB): EMA has adopted a negative opinion on MAA of Lecanemab for early Alzheimer’s disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Biogen (BIIB) PT Lowered to $294 at Baird
July 29, 2024 6:56 AM EDTBaird analyst Brian Skorney lowered the price target on Biogen (NASDAQ: BIIB) to $294.00 (from $316.00) while maintaining a Outperform rating.
The analyst comments "Lowering target on negative CHMP opinion. The initial negative opinion jeopardizes Leqembi's launch in the EU, where we had... More
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB), 'We next await the August 1 earnings call'
July 26, 2024 12:18 PM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $342.00 price target on Biogen (NASDAQ: BIIB)
The analyst comments "The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion for BIIB/Eisais Leqembi, stating that the slowing of cognitive decline in treated patients does not outweigh the safety risks... More
Biogen (BIIB) PT Lowered to $307 at Piper Sandler
July 26, 2024 10:40 AM EDTPiper Sandler analyst Christopher Raymond lowered the price target on Biogen (NASDAQ: BIIB) to $307.00 (from $313.00) while maintaining a Overweight rating.
The analyst comments "Conclusion: Remain OW on BIIB shares despite news this morning that the EMAs Committee for Medicinal Products for Human... More
Biogen (BIIB) PT Lowered to $282 at RBC Capital
July 26, 2024 10:10 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $282.00 (from $303.00) while maintaining a Outperform rating.
The analyst comments "Our analysis suggests a 20% historical success rate for drugs CHMP re-examines; looking at prior examples over the past 10 years, we... More
